465 assets in Obesity Disorder

Therapeutic assets addressing Obesity Disorder, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Acetic Acid, Sodium Salt (1:1) Obesity Disorder	Columbia University	P1	CC (43)
Akk Obesity Disorder	Central South University	P2	CC (43)
Alpelisib Obesity Disorder	Columbia University	P1	CC (43)
Azelaprag Obesity Disorder	BioAge Labs, Inc.	P2	CC (43)
bi 3034701 Obesity Disorder	Boehringer Ingelheim	P2	CC (43)
Bis-Octanoyl -1,3-Butanediol Obesity Disorder	Washington University School of Medicine	P2	CC (43)
Bremelanotide Obesity Disorder	Palatin Technologies, Inc	P2	CC (43)
Crb-913 Obesity Disorder	Corbus Pharmaceuticals Inc.	P1	CC (43)
cs060380 Obesity Disorder	Cascade Pharmaceuticals, Inc	P2	CC (43)
D-Thioctic Acid Obesity Disorder	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	P2	CC (43)
Epigallocatechin-3-Gallate Obesity Disorder	Purdue University	P2	CC (43)
Glycerin,Anhydrous Obesity Disorder	Rutgers, The State University of New Jersey	P2	CC (43)
gs-4571 Obesity Disorder	Gilead Sciences	P1	CC (43)
ht-6184 Obesity Disorder	Halia Therapeutics, Inc.	P2	CC (43)
Ibio-600 Obesity Disorder	iBio, Inc.	P1	CC (43)
Kbp-336 Obesity Disorder	KeyBioscience AG	P2	CC (43)
lae103 Obesity Disorder	Laekna Limited	P1	CC (43)
L-Ctirulline Obesity Disorder	University of Colorado, Denver	P2	CC (43)
ly6249492 Obesity Disorder	Eli Lilly and Company	P2	CC (43)
mbl949 Obesity Disorder	Novartis Pharmaceuticals	P2	CC (43)
mkp10241 Obesity Disorder	Mankind Pharma Limited	P2	CC (43)
Multiple Vitamins Injection Obesity Disorder	Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau	P2	CC (43)
Nabilone Obesity Disorder	Centre for Addiction and Mental Health	P2	CC (43)
Nimacimab Obesity Disorder	Skye Bioscience, Inc.	P2	CC (43)
nt-0796 Obesity Disorder	NodThera Limited	P2	CC (43)
Pegargiminase Obesity Disorder	Washington University School of Medicine	P2	CC (43)
Relebactam Obesity Disorder	University of Illinois at Chicago	P4	CC (43)
Repaglinide Obesity Disorder	Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.	P1	CC (43)
Ribupatide Obesity Disorder	Kailera	P2	CC (43)
SA030 Obesity Disorder	Suzhou Siran Biotechnology Co.,Ltd.	P1	CC (43)
(S)-(-)-Pindolol Benzoate Obesity Disorder	Actimed Therapeutics Ltd	P2	CC (43)
Sucralose Obesity Disorder	Virginia Polytechnic Institute and State University	P2	CC (43)
Taldefgrobep Alfa Obesity Disorder	Biohaven Therapeutics Ltd.	P2	CC (43)
Trevogrumab Obesity Disorder	Regeneron Pharmaceuticals	P2	CC (43)
Vericiguat Obesity Disorder	University of Alabama at Birmingham	P2	CC (43)
VX-201 Obesity Disorder	Terrestrial Bio, Inc.	P1	CC (43)
bi 1820237 Obesity Disorder	Boehringer Ingelheim	P1	CC (42)
Ethinyl Estradiol Obesity Disorder	Amgen	P1	CC (42)
Iohexol Obesity Disorder	University of Colorado, Denver	P1/2	CC (42)
Itraconazole Obesity Disorder	Shionogi	P1	CC (42)
L-Cysteinamide, D-Phenylalanyl-L-Cysteinyl-L-Phenylalanyl-D-Tryptophyl-L-Lysyl-L-Threonyl-N-(2-Hydroxy-1-(Hydroxymethyl)Propyl)-, Cyclic (2->7)-Disulfide, (R-(R,R))- Obesity Disorder	Columbia University	P1	CC (42)
Moxifloxacin Obesity Disorder	Amgen	P1	CC (42)
Omeprazole Obesity Disorder	Shandong Suncadia Medicine Co., Ltd.	P1	CC (42)
pb-119 Obesity Disorder	PegBio Co., Ltd.	P1/2	CC (42)
pb-718 Obesity Disorder	PegBio Co., Ltd.	P1/2	CC (42)
Sodium P-Aminohippurate Obesity Disorder	University of Colorado, Denver	P1/2	CC (42)
bgm1812 Obesity Disorder	BrightGene Bio-Medical Technology Co., Ltd.	P1	CC (41)
Dexasone Obesity Disorder	University of North Carolina, Chapel Hill	P1	CC (41)
DWC202502 Obesity Disorder	Daewoong Pharmaceutical Co. LTD.	P1	CC (41)
DWC202503 Obesity Disorder	Daewoong Pharmaceutical Co. LTD.	P1	CC (41)

Showing 251 to 300 of 465 assets

PreviousPage 6 of 10Next